Showing results (61-70 of 77) with videos related to
Sort By:
Pageof 8
Oral Oncology|August 27, 2019
Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trialRobert Haddad, Joel Guigay, Ulrich Keilholz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion CohortLaura Q M Chow, Robert Haddad, Shilpa Gupta, et al.The New England Journal of Medicine|October 11, 2016
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckRobert L Ferris, George Blumenschein, Jerome Fayette, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2023
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaSophie Wildsmith, Weimin Li, Song Wu, et al.Journal for Immunotherapy of Cancer|January 21, 2022
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer respondersLiye Zhou, Zexian Zeng, Ann Marie Egloff, et al.JAMA|March 13, 2025
Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical TrialRobert Haddad, Jérôme Fayette, Maria Teixeira, et al.The Lancet. Oncology|June 28, 2017
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trialKevin J Harrington, Robert L Ferris, George Blumenschein, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2021
Tipifarnib in Head and Neck Squamous Cell Carcinoma With <i>HRAS</i> MutationsAlan L Ho, Irene Brana, Robert Haddad, et al.The Lancet. Digital Health|April 22, 2023
Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trialBenjamin H Kann, Jirapat Likitlersuang, Dennis Bontempi, et al.JAMA Oncology|April 6, 2023
Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical TrialKevin J Harrington, Robert L Ferris, Maura Gillison, et al.Pageof 8